Clinical features of hydronephrosis induced by retroperitoneal fibrosis: 17 cases reports

  • Shi-bo LIU ,
  • Hui GAO ,
  • Yuan-chun FENG ,
  • Jing LI ,
  • Tong ZHANG ,
  • Li WAN ,
  • Yan-ying LIU ,
  • Sheng-guang LI ,
  • Cheng-hua LUO ,
  • Xue-wu ZHANG
Expand
  • 1. Department of Retroperitoneal Tumor Surgery
    2.Department of Rheumatology and Immunology
    3. Department of Radiology
    4. Department of Laboratory Medicine
    5. Department of Pathology
    6. Department of Nephrology, Peking University International Hospital, Beijing 102206, China
    7. Department of Rheumatology and Immunology, Peking University People’s Hospital, Beijing 100044, China

Received date: 2020-07-31

  Online published: 2020-12-13

Supported by

Peking University International Hospital Research Grant(YN2019QN02)

Abstract

Objective: To investigate the clinical features and outcome of hydronephrosis induced by retroperitoneal fibrosis (RPF), and to evaluate the effect of corticosteroid based therapy combined with surgical intervention of ureteral obstruction. Methods: A total of 17 RPF patients with hydronephrosis hospitalized in Peking University International Hospital from May 2016 to December 2019 were analyzed retrospectively. Results: The median age was 56 (53, 65) years, the male to female ratio was 2.4:1, and the disease duration was 4.00 (0.83, 8.00) months. The initial symptoms included back pain (9 cases), abdominal pain (6 cases), oliguria (2 cases) and lower limb edema (3 cases). Eight patients presented left hydronephrosis, 1 right hydronephrosis and 8 bilateral hydronephrosis. C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) were both elevated in 13 patients (76.5%, n=17). Immunoglobin (Ig) G4 increased in 5 cases (29.4%, n=17). IgG, IgE and IgA increased in 4 cases (30.8%, n=13), 4 cases (30.8%, n=13) and 1 case (7.7%, n=13), respectively. Among 12 patients who underwent biopsy, 3 patients were diagnosed with IgG4-relate disease. The level of IgG4 in the tissues varied, 6 cases expressed less than 10 per high power field (HPF) or no expression (50.0%). Only 2 cases expressed 10-30/HPF (16.7%), and 4 cases revealed more than 30/HPF (33.3%). Among the 17 patients with ureteral obstruction, no urinary drainage procedure was needed in 4 patients who had mild ureteral obstruction, whereas, ureteral stenting was carried out in the other 13 cases before drug treatment. Time was too short to evaluate the effect of urinary drainage procedures in 4 patients. For the rest, ureterolysis had to be performed in 3 cases after failed ureteral stent insertion. Successful drain removal was accomplished in all of these 9 patients and the mean time to drain removal was (6.7±3.0) months. In addition, 10 patients had complete medical records after an average follow-up time of 5 (3-13) months. Levels of ESR, CRP, IgG4, IgG, IgE, IgA were 54.0 (36.3, 98.5) mm/h, 26.8 (8.7, 53.0) mg/L, 1.34 (0.55, 3.36) g/L, 16.3 (13.0, 21.1) g/L, 40.5 (31.4, 203.0) IU/mL, 2.51 (1.82, 3.25) g/L at baseline, which all decreased predominantly after treatment. ESR, CRP, IgG4, IgG, IgE and IgA dropped by 38.5 (23.5, 54.3) mm/h (P<0.01), 23.0 (5.5, 52.0) mg/L (P<0.05), 0.92 (0.40, 2.85) g/L (P<0.01), 6.5 (1.7, 9.1) g/L (P<0.05), 23.7 (4.8, 162.0) IU/mL (P<0.05) and 0.77 (0.32, 1.26) g/L (P<0.05), respectively. Size of mass measured by CT/MRI imaging became smaller significantly and hydronephrosis relieved. Conclusion: Onset of RPF is insidious and lack of specific initial symptoms. Corticosteroid based therapy combined with surgical intervention of relieving obstruction is effective.

Cite this article

Shi-bo LIU , Hui GAO , Yuan-chun FENG , Jing LI , Tong ZHANG , Li WAN , Yan-ying LIU , Sheng-guang LI , Cheng-hua LUO , Xue-wu ZHANG . Clinical features of hydronephrosis induced by retroperitoneal fibrosis: 17 cases reports[J]. Journal of Peking University(Health Sciences), 2020 , 52(6) : 1069 -1074 . DOI: 10.19723/j.issn.1671-167X.2020.06.013

References

[1] Uibu T, Oksa P, Auvinen A, et al. Asbestos exposure as a risk factor for retroperitoneal fibrosis[J]. Lancet, 2004,363(9419):1422-1426.
[2] Vaglio A, Palmisano A, Alberici F, et al. Prednisone versus tamoxifen in patients with idiopathic retroperitoneal fibrosis: An open-label randomised controlled trial[J]. Lancet, 2011,378(9788):338-346.
[3] Scheel PJ Jr, Feeley N. Retroperitoneal fibrosis: the clinical, laboratory, and radiographic presentation[J]. Medicine (Baltimore), 2009,88(4):202-207.
[4] Deshpande V, Zen Y, Chan JK, et al. Consensus statement on the pathology of IgG4-related disease[J]. Mod Pathol, 2012,25(9):1181-1192.
[5] Ormond JK. Bilateral ureteral obstruction due to envelopment and compression by an inflammatory retroperitoneal process[J]. J Urol, 1948,59(6):1072-1079.
[6] Zen Y, Onodera M, Inoue D, et al. Retroperitoneal fibrosis: A clinicopathologic study with respect to immunoglobulin G4[J]. Am J Surg Pathol, 2009,33(12):1833-1839.
[7] Rossi GM, Rocco R, Accorsi Buttini E, et al. Idiopathic retroperitoneal fibrosis and its overlap with IgG4-related disease[J]. Intern Emerg Med, 2017,12(3):287-299.
[8] Yamashita K, Haga H, Mikami Y, et al. Degree of IgG4+ plasma cell infiltration in retroperitoneal fibrosis with or without multifocal fibrosclerosis[J]. 2010,52(3):404-409.
[9] Khosroshahi A, Carruthers MN, Stone JH, et al. Rethinking Ormond's disease: "idiopathic" retroperitoneal fibrosis in the era of IgG4-related disease[J]. Medicine (Baltimore), 2013,92(2):82-91.
[10] Caiafa RO, Vinuesa AS, Izquierdo RS, et al. Retroperitoneal fibrosis: Role of imaging in diagnosis and follow-up[J]. Radiographics, 2013,33(2):535-552.
[11] George V, Tammisetti VS, Surabhi VR, et al. Chronic fibrosing conditions in abdominal imaging[J]. Radiographics, 2013,33(4):1053-1080.
[12] Pelkmans LG, Aarnoudse AJ, Hendriksz TR, et al. Value of acute-phase reactants in monitoring disease activity and treatment response in idiopathic retroperitoneal fibrosis[J]. Nephrol Dial Transplant, 2012,27(7):2819-2825.
[13] van Bommel EF, Siemes C, Hak LE, et al. Long-term renal and patient outcome in idiopathic retroperitoneal fibrosis treated with prednisone[J]. Am J Kidney Dis, 2007,49(5):615-625.
[14] Fry AC, Singh S, Gunda SS, et al. Successful use of steroids and ureteric stents in 24 patients with idiopathic retroperitoneal fibrosis: A retrospective study[J]. Nephron Clin Pract, 2008,108(3):c213-220.
[15] Alberici F, Palmisano A, Urban ML, et al. Methotrexate plus prednisone in patients with relapsing idiopathic retroperitoneal fibrosis[J]. Ann Rheum Dis, 2013,72(9):1584-1586.
[16] Scheel PJ Jr, Feeley N, Sozio SM. Combined prednisone and mycophenolate mofetil treatment for retroperitoneal fibrosis: a case series[J]. Ann Intern Med, 2011,154(1):31-36.
[17] Binder M, Uhl M, Wiech T, et al. Cyclophosphamide is a highly effective and safe induction therapy in chronic periaortitis: a long-term follow-up of 35 patients with chronic periaortitis[J]. Ann Rheum Dis, 2012,71(2):311-312.
[18] Li KP, Zhu J, Zhang JL, et al. Idiopathic retroperitoneal fibrosis (RPF): Clinical features of 61 cases and literature review[J]. Clin Rheumatol, 2011,30(5):601-605.
[19] Vaglio A, Maritati F. Idiopathic retroperitoneal fibrosis[J]. J Am Soc Nephrol, 2016,27(7):1880-1889.
[20] Mertens S, Zeegers AG, Wertheimer PA, et al. Efficacy and complications of urinary drainage procedures in idiopathic retroperitoneal fibrosis complicated by extrinsic ureteral obstruction[J]. Int J Urol, 2014,21(3):283-288.
[21] Cristian S, Cristian M, Cristian P, et al. Management of idiopathic retroperitoneal fibrosis from the urologist's perspective[J]. Ther Adv Urol, 2015,7(2):85-99.
Outlines

/